Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock Holdings Decreased by SG Americas Securities LLC

SG Americas Securities LLC reduced its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTLGet Rating) by 49.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,834 shares of the company’s stock after selling 9,650 shares during the period. SG Americas Securities LLC’s holdings in Zentalis Pharmaceuticals were worth $454,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. DekaBank Deutsche Girozentrale increased its position in shares of Zentalis Pharmaceuticals by 10.3% in the first quarter. DekaBank Deutsche Girozentrale now owns 15,050 shares of the company’s stock worth $686,000 after acquiring an additional 1,400 shares in the last quarter. Values First Advisors Inc. purchased a new position in Zentalis Pharmaceuticals during the fourth quarter valued at approximately $214,000. Walleye Capital LLC purchased a new position in Zentalis Pharmaceuticals during the fourth quarter valued at approximately $1,121,000. Ghost Tree Capital LLC grew its position in Zentalis Pharmaceuticals by 23.1% during the fourth quarter. Ghost Tree Capital LLC now owns 80,000 shares of the company’s stock valued at $6,725,000 after purchasing an additional 15,000 shares in the last quarter. Finally, Perceptive Advisors LLC purchased a new position in Zentalis Pharmaceuticals during the fourth quarter valued at approximately $36,192,000. 95.01% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Zentalis Pharmaceuticals

In other news, COO Kevin D. Bunker sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $30.07, for a total transaction of $751,750.00. Following the completion of the transaction, the chief operating officer now directly owns 110,000 shares in the company, valued at $3,307,700. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, COO Kevin D. Bunker sold 25,000 shares of the business’s stock in a transaction dated Tuesday, July 5th. The shares were sold at an average price of $30.07, for a total transaction of $751,750.00. Following the transaction, the chief operating officer now owns 110,000 shares in the company, valued at approximately $3,307,700. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Kevin D. Bunker sold 5,000 shares of the business’s stock in a transaction dated Wednesday, July 20th. The stock was sold at an average price of $30.00, for a total transaction of $150,000.00. Following the transaction, the chief operating officer now owns 100,000 shares in the company, valued at approximately $3,000,000. The disclosure for this sale can be found here. Insiders sold a total of 31,710 shares of company stock worth $953,084 in the last 90 days. 19.90% of the stock is owned by company insiders.

Zentalis Pharmaceuticals Trading Up 0.1 %

Shares of Zentalis Pharmaceuticals stock opened at $30.72 on Friday. The firm has a fifty day simple moving average of $27.36 and a 200-day simple moving average of $35.73. The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of -7.98 and a beta of 1.88. Zentalis Pharmaceuticals, Inc. has a 1-year low of $17.33 and a 1-year high of $87.19.

Zentalis Pharmaceuticals (NASDAQ:ZNTLGet Rating) last released its quarterly earnings results on Thursday, May 5th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same quarter in the prior year, the company posted ($1.24) EPS. As a group, research analysts predict that Zentalis Pharmaceuticals, Inc. will post -4.9 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently commented on ZNTL shares. Wedbush lowered their price objective on shares of Zentalis Pharmaceuticals from $71.00 to $51.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 10th. Oppenheimer lowered their price objective on shares of Zentalis Pharmaceuticals from $100.00 to $85.00 and set an “outperform” rating on the stock in a research report on Tuesday, April 12th. SVB Leerink lowered their price objective on shares of Zentalis Pharmaceuticals from $78.00 to $67.00 and set an “outperform” rating on the stock in a research report on Tuesday, April 12th. Cowen assumed coverage on shares of Zentalis Pharmaceuticals in a research note on Tuesday, July 12th. They issued an “outperform” rating for the company. Finally, Cowen assumed coverage on shares of Zentalis Pharmaceuticals in a research note on Tuesday, July 12th. They issued an “outperform” rating for the company. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, Zentalis Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $74.43.

About Zentalis Pharmaceuticals

(Get Rating)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.

Featured Stories

Want to see what other hedge funds are holding ZNTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTLGet Rating).

Institutional Ownership by Quarter for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.